SARS-CoV-2 spike protein peptide 12 epitope (P12 epitope)

The SARS-CoV-2 spike protein peptide 12 epitope is a linear B-cell epitope located within the S1 subunit of the viral spike (S) glycoprotein, specifically encompassing amino acid residues 284 to 313. This region is situated at the C-terminal end of the N-terminal domain (NTD), making it physically proximal to the receptor-binding domain (RBD). Research has highlighted this epitope as a key target for neutralizing antibodies, particularly in individuals vaccinated with Gam-COVID-Vac (Sputnik V). Unlike antibodies that target the RBD to directly block the interaction with the human ACE2 receptor, antibodies specific to the peptide 12 epitope are thought to neutralize the virus by preventing the conformational change of the spike protein from its pre-fusion to post-fusion state. This epitope is notable for its high degree of conservation across various SARS-CoV-2 variants, including the Omicron lineage, suggesting its potential as a target for broad-spectrum vaccine development and therapeutic monoclonal antibody interventions.

Other names

S284-313 epitopeSpike protein residues 284-313S1 peptide 12 epitopeSARS-CoV-2 S1-P12

Antibodies targeting this epitope neutralize the virus by interfering with the conformational transition of the spike protein from its pre-fusion to post-fusion state, thereby preventing membrane fusion and viral entry into host cells.